You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary mediastinal [thymic] large B-cell lymphoma (PMBCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

    Active, not recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • DISEASE
    • (no location specified)
    May 4, 2023

    Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

    Available
    • Large B-cell Lymphoma
    • +4 more
    • Epcoritamab
    • (no location specified)
    Feb 16, 2023

    Cardiovascular Events Among Adults Relapsed or Refractory

    Recruiting
    • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
    • +9 more
    • Electronic Health Record Review
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +11 more
    • Biopsy
    • +5 more
    • Duarte, California
      City of Hope Medical Center
    Jan 3, 2023

    Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

    Active, not recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +8 more
    • Anakinra
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2022

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    Bio-CAR-T BS Study

    Recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • +2 more
      • Brescia, Italy
        ASST Spedali Civili di Brescia
      May 5, 2022

      B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

      Recruiting
      • B-Cell Non-Hodgkin Lymphoma
      • +7 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Dec 9, 2022

      Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

      Not yet recruiting
      • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
      • +21 more
      • Biopsy
      • +8 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Apr 7, 2023

      Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • +5 more
      • La Jolla, California
      • +7 more
      Aug 25, 2023

      Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

      Active, not recruiting
      • Aggressive Non-Hodgkin Lymphoma
      • +13 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Aug 18, 2022

      Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

      Withdrawn
      • Recurrent Diffuse Large B-Cell Lymphoma
      • +9 more
      • Autologous Hematopoietic Stem Cell Transplantation
      • +5 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 11, 2023

      Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

      Active, not recruiting
      • Recurrent B-Cell Non-Hodgkin Lymphoma
      • +7 more
      • Jacksonville, Florida
      • +11 more
      Jan 12, 2023

      Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

      Not yet recruiting
      • Recurrent ALK Positive Large B-Cell Lymphoma
      • +28 more
      • Biospecimen Collection
      • +5 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Aug 17, 2022

      Communication Training Intervention for Large B-Cell Lymphoma

      Recruiting
      • Lymphoma, B-Cell
      • +5 more
      • Hematolo-GIST Training
      • Participants Appointment
      • New York, New York
      • +2 more
      Jul 3, 2023

      Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large

      Recruiting
      • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
      • +3 more
      • Brentuximab Vedotin
      • +6 more
      • Houston, Texas
        M D Anderson Cancer Center
      Feb 10, 2022

      Lymphoma, B-Cell Trial in Japan (Pembrolizumab)

      Active, not recruiting
      • Lymphoma, B-Cell
      • Nagoya, Aichi, Japan
      • +8 more
      Aug 18, 2022

      DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

      Terminated
      Has Results
      • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
      • +5 more
      • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
      • +3 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Aug 1, 2022

      Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • (no location specified)
      Mar 9, 2023

      Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

      Recruiting
      • Non Hodgkin Lymphoma (NHL)
      • +6 more
      • 8/12-Day Production of Car-T Cells
      • +2 more
      • Milwaukee, Wisconsin
        Medical College of Wisconsin and Froedtert Hospital
      Jul 1, 2022

      Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL) Trial in

      Recruiting
      • Diffuse Large-Cell Lymphoma
      • +3 more
      • Pneumococcal conjugate vaccine (PCV13)
      • CD19 targeted CAR T Cell Therapy
      • Tampa, Florida
        Moffitt Cancer Center
      May 31, 2022